Posted by Michael Wonder on 23 Jan 2024
Theratechnologies receives update from FDA on tesamorelin F8 supplemental biologics license application
23 January 2024 - FDA continues to review the file past the Prescription Drug User Fee Act goal date of 22 January 2024.
Theratechnologies has received correspondence from the US FDA regarding the Company’s supplemental biologics license application for the F8 formulation of tesamorelin.
